GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information. Health and ancestry service ...

The widespread use of PCR in DNA and RNA analysis makes this an ... Customers include AstraZeneca, Merck and GlaxoSmithKline. One of the biggest growth markets for applying microfluidics in ...

Job cuts at its Centres of Excellence for Drug Discovery (CEDD) in the US, UK and Italy, accompanied by an expansion of research in China, are raising questions about where GlaxoSmithKline (GSK ...

GSK has revealed updated results from its phase ... resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants with ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

GSK GSK-0.10%decrease; red down pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...